Clinical Topics & News
LOS ANGELES – A “dramatically different” landscape of treatment options allows better tailoring to patients, authors say.
A single dynamic contrast-enhanced MRI scan at 6 months was predictive in patients taking natalizumab or fingolimod.
New reports reveal rare adverse events in the treatment of relapsing-remitting multiple sclerosis using alemtuzumab.
Cannabis extract, physical activity, and cognitive behavioral therapy are complementary and alternative medicines (CAMs) with the strongest...
Safety results and potential efficacy point to possible future clinical development.
But the absolute difference in the rate of confirmed disability progression versus placebo was small.
Correlation also observed between viral load and lesion volume.
Researchers are getting closer to identifying MS patients more susceptible to secondary autoimmunity after alemtuzumab treatment.
SAN DIEGO – Evidence of remyelination observed at 24 weeks.
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have published a...